Announcements Trials
Browse Landscape

Status

Recruiting 1Enrolling by invitation 1

Sponsor Class

OTHER 2

Study Type

Interventional 10Observational 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Myeloid 2

Conditions

Leukemia, Myelogenous, Chronic, BCR-ABL Positive 2

Interventions

Surveys and Questionnaires 529Blood Specimen Collection 406Surgical Procedures, Operative 151Radiotherapy 131Interviews as Topic 131Drug Therapy 123Observation 122Magnetic Resonance Spectroscopy 104Biopsy 103Specimen Handling 70Data Collection 70Neoadjuvant Therapy 65Immunohistochemistry 64Magnetic Resonance Imaging 61Immune Checkpoint Inhibitors 59Watchful Waiting 52Immunotherapy 51Bevacizumab 50Positron Emission Tomography Computed Tomography 46Ultrasonography 44Hematologic Tests 42Liquid Biopsy 41Tomography, X-Ray Computed 40Therapeutics 40Radiosurgery 40Colonoscopy 40pembrolizumab 37Hepatectomy 37Gene Expression Profiling 36High-Energy Shock Waves 35

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
OTHER × Observational × olverembatinib × Clear all
NCT07383298 2026-02-03

Observational Study on Dose Optimization of Olverembatinib in Patients With Chronic Myeloid Leukemia in Chronic or Accelerated Phase

Peking University People's Hospital

Enrolling by invitation
100 enrolled
MyeloidOther hematologic neoplasm

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT06390306 2025-06-03

The Efficacy and Safety of Third-generation TKIs Combined With Azacitidine and Bcl-2 Inhibitor in Patients With CML-MBP

Peking University People's Hospital

Recruiting
30 enrolled
MyeloidOther hematologic neoplasm

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Data powered by HemOnc (CC BY 4.0) Colophon âš¡